PMID- 30589082
OWN - NLM
STAT- MEDLINE
DCOM- 20200217
LR  - 20231006
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 196
IP  - 1
DP  - 2019 Apr
TI  - Dendritic cells, T cells and their interaction in rheumatoid arthritis.
PG  - 12-27
LID - 10.1111/cei.13256 [doi]
AB  - Dendritic cells (DCs) are the key professional antigen-presenting cells which 
      bridge innate and adaptive immune responses, inducing the priming and 
      differentiation of naive to effector CD4(+) T cells, the cross-priming of CD8(+) 
      T cells and the promotion of B cell antibody responses. DCs also play a critical 
      role in the maintenance of immune homeostasis and tolerance. DC-T cell 
      interactions underpin the generation of an autoimmune response in rheumatoid 
      arthritis (RA). Here we describe the function of DCs and review evidence for DC 
      and T cell involvement in RA pathogenesis, in particular through the presentation 
      of self-peptide by DCs that triggers differentiation and activation of 
      autoreactive T cells. Finally, we discuss the emerging field of targeting the 
      DC-T cell interaction for antigen-specific immunotherapy of RA.
CI  - (c) 2018 British Society for Immunology.
FAU - Wehr, P
AU  - Wehr P
AD  - The University of Queensland Diamantina Institute, Translational Research 
      Institute, Princess Alexandra Hospital, Brisbane, Australia.
FAU - Purvis, H
AU  - Purvis H
AD  - King's College London, Academic Department of Rheumatology, Centre for 
      Inflammation Biology and Cancer Immunology, School of Immunology and Microbial 
      Sciences, Faculty of Life Sciences and Medicine, London, UK.
FAU - Law, S-C
AU  - Law SC
AD  - The University of Queensland Diamantina Institute, Translational Research 
      Institute, Princess Alexandra Hospital, Brisbane, Australia.
FAU - Thomas, R
AU  - Thomas R
AUID- ORCID: 0000-0002-0518-8386
AD  - The University of Queensland Diamantina Institute, Translational Research 
      Institute, Princess Alexandra Hospital, Brisbane, Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190121
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Autoantigens)
RN  - 0 (Peptides)
SB  - IM
MH  - Animals
MH  - Antibody Formation
MH  - Antigen Presentation
MH  - Arthritis, Rheumatoid/*immunology
MH  - Autoantigens/immunology/metabolism
MH  - Autoimmunity
MH  - B-Lymphocytes/*immunology
MH  - Cell Communication
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immune Tolerance
MH  - Immunotherapy/*methods
MH  - Lymphocyte Activation
MH  - Peptides/immunology/metabolism
MH  - T-Lymphocytes/*immunology
PMC - PMC6422662
OTO - NOTNLM
OT  - antigen presentation
OT  - autoantigen-specific CD4+ T cells
OT  - autoimmunity
OT  - dendritic cells
OT  - immunotherapy
OT  - rheumatoid arthritis
COIS- R. T. has filed provisional patents surrounding technology for targeting DCs for 
      antigen-specific tolerance, and is a director of the spin-off company, Dendright, 
      which is commercializing immunotherapy to target DCs to suppress rheumatoid 
      arthritis in collaboration with Janssen Biotech Inc. R. T. has also received 
      speaker fees and/or consulting fees from Janssen and Abbvie.
EDAT- 2018/12/28 06:00
MHDA- 2020/02/18 06:00
PMCR- 2020/04/01
CRDT- 2018/12/28 06:00
PHST- 2018/12/10 00:00 [accepted]
PHST- 2018/12/28 06:00 [pubmed]
PHST- 2020/02/18 06:00 [medline]
PHST- 2018/12/28 06:00 [entrez]
PHST- 2020/04/01 00:00 [pmc-release]
AID - CEI13256 [pii]
AID - 10.1111/cei.13256 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2019 Apr;196(1):12-27. doi: 10.1111/cei.13256. Epub 2019 Jan 
      21.